Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02708576




Registration number
NCT02708576
Ethics application status
Date submitted
29/02/2016
Date registered
15/03/2016
Date last updated
14/09/2017

Titles & IDs
Public title
Phase 1 Study of NGM313 in Healthy Adult Participants
Scientific title
A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants
Secondary ID [1] 0 0
15-0201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Obesity 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - NGM313
Other interventions - Placebo

Experimental: NGM313 - Administration of active NGM313

Placebo Comparator: Placebo - Administration of placebo comparator


Other interventions: NGM313


Other interventions: Placebo
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Absolute change in weight in kilograms
Timepoint [1] 0 0
28 and 84 days
Secondary outcome [1] 0 0
Absolute change in fasting glucose in mmol/L
Timepoint [1] 0 0
28 and 84 days

Eligibility
Key inclusion criteria
- BMI range 27-40 kg/m2, inclusive for the SAD module, and 27-40 kg/m2, inclusive for
the MAD module;

- Normal clinical laboratory evaluations

- Normal ECG findings
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
- Significant history or clinical manifestation of any significant metabolic, allergic,
dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,
gastrointestinal, neurological, or psychiatric disorder

- Uncontrolled hypertension defined as sitting blood pressure systolic > 150 mm/Hg
and/or diastolic > 90 mm/Hg

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Factorial
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/02/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2017
Sample size
Target
Accrual to date
Final
151
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
NGM Clinical Study Site - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
NGM Biopharmaceuticals, Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the safety and tolerability of NGM313, both single
dose and multiple doses, in normal healthy overweight and obese adult participants.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02708576
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Que Liu, MD
Address 0 0
NGM Biopharmaceuticals, Inc
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02708576